McAnear Justin J. 4

4 · Alamar Biosciences, Inc. · Filed Apr 20, 2026

AI-generated summary of this filing

Updated Apr 21, 2026

Alamar Biosciences (ALMR) CFO Justin McAnear Receives RSUs

What Happened

Justin J. McAnear, Chief Financial Officer of Alamar Biosciences (ALMR), was granted 37,220 restricted stock units (RSUs) on 2026-04-20 at $0.00 and the filing also reports a 163,358-share derivative award (acquired on 2026-04-16, $0) plus same-day “other” disposition and acquisition entries of 570,719 derivative shares on 2026-04-20 (all at $0.00). No cash changed hands in these reported entries; the $0 price indicates awards or internal reclassifications/conversions rather than open-market trades.

Key Details

Filing date: 2026-04-20; Period of Report: 2026-04-16. Filing appears timely.
Transactions and prices:
- 2026-04-20: RSU grant — 37,220 shares @ $0.00 (acquired).
- 2026-04-16: Derivative award — 163,358 shares @ $0.00 (acquired).
- 2026-04-20: Other disposition — 570,719 derivative shares @ $0.00 (disposed).
- 2026-04-20: Other acquisition — 570,719 derivative shares @ $0.00 (acquired).
Shares owned after these transactions: Not specified in the excerpt of the filing provided.
No cash proceeds reported; transactions are awards/conversions (derivative transactions), not open-market buys/sells.
Footnotes provided in the filing:
- F1: RSUs — vest monthly from grant date, subject to continued service.
- F2: Option vesting — 25% vests 4/16/2027, then 1/48th monthly thereafter (service condition).
- F3: Class B common shares were reclassified to Common Stock immediately before the IPO.
- F4: Option vesting — 25% vests 10/13/2026, then 1/48th monthly thereafter (service condition).

Context

These entries reflect compensation-related awards and derivative reclassifications/conversions rather than open-market purchases or sales. RSU grants and option awards are common executive compensation and typically vest over time; they do not by themselves indicate immediate buying or selling in the market.
The paired 570,719 “other” disposition and acquisition at $0 likely reflect an internal conversion or reclassification of derivative holdings (see F3) rather than a sale; the filing does not show cash proceeds.
For retail investors, awards (like RSUs) are less immediately informative about insider sentiment than open-market purchases, since they are compensation-related and subject to vesting and service conditions.

Form 4

Period: 2026-04-16

Chief Financial Officer

Transactions

Award
Common Stock
[F1]
2026-04-20+37,220→ 37,220 total
Award
Stock Option (Right to Buy)
[F2]
2026-04-16+163,358→ 163,358 total
Exercise: $17.00Exp: 2036-04-15→ Common Stock (163,358 underlying)
Other
Stock Option (Right to Buy)
[F3][F4]
2026-04-20−570,719→ 0 total
Exercise: $4.62Exp: 2035-10-14→ Class B Common Stock (570,719 underlying)
Other
Stock Option (Right to Buy)
[F3][F4]
2026-04-20+570,719→ 570,719 total
Exercise: $4.62Exp: 2035-10-14→ Common Stock (570,719 underlying)

Footnotes (4)

[F1]Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date.
[F2]Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date.
[F3]Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock.
[F4]Twenty-five percent of the shares subject to the option vest on October 13, 2026, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date.

Signature

/s/ Timothy White, Attorney-in-Fact|2026-04-20

1 file